Do interleukin-6, hyaluronan, soluble intercellular adhesion molecule-1 and cancer antigen 125 in dialysate predict changes in peritoneal function?

References

• Davies SJ, Bryan J, Phillips L, Russell GI. Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 1996; 11: 498–506
   PubMed Web of Science ®Google Scholar
• Davies SJ, Phillips L, Naish PF, Russell GI. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol 2001; 12: 1046–51
   PubMed Web of Science ®Google Scholar
• Topley N. Membrane longevity in peritoneal dialysis: impact of infection and bio-incompatible solutions. Adv Renal Repl Ther 1998; 5: 179–84
   PubMedGoogle Scholar
• Heimburger O, Wang T, Lindholm B. Alterations in water and solute transport with time on peritoneal dialysis. Perit Dial Int 1999; 19: S83–90
   PubMed Web of Science ®Google Scholar
• Davies SJ, Phillips L, Russell GI. Peritoneal solute transport predicts survival on CAPD independently of residual renal function. Nephrol Dial Transplant 1998; 13: 962–8
   PubMed Web of Science ®Google Scholar
• Mateijsen MA, van der Wal AC, Hendriks PM, Zweers MM, Mulder J, Struijk DG, et al. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int 1999; 19: 517–25
   PubMed Web of Science ®Google Scholar
• Lai KN, Lai KB, Lam CW, Chan TM, Li FK, Leung JC. Changes of cytokine profiles during peritonitis in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 2000; 35: 644–52
   PubMed Web of Science ®Google Scholar
• Martikainen T, Ekstrand A, Honkanen E, Teppo A, Gronhagen-Riska C. Dialysate leukocytes, sICAM-1, hyaluronan and IL-6: predictors of outcome of peritonitis?. Blood Purif 2004; 22: 360–6
   PubMed Web of Science ®Google Scholar
• Pecoits-Filho R, Araujo MR, Lindholm B, Stenvinkel P, Abensur H, Romao JE, Jr, et al. Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate. Nephrol Dial Transplant 2002; 17: 1480–6
   PubMed Web of Science ®Google Scholar
• Peers E, Gokal R. Icodextrin provides long dwell peritoneal dialysis and maintenance of intraperitoneal volume. Artif Organs 1998; 22: 8–12
   PubMed Web of Science ®Google Scholar
• Barre DE, Chen C, Cooker L, Moberly JB. Decreased in vitro formation of AGEs with extraneal solution compared to dextrose-containing peritoneal dialysis solutions. Adv Perit Dial 1999; 15: 12–6
   PubMedGoogle Scholar
• Cooker LA, Choo CG, Luneburg P, Lamela J, Holmes CJ. Effect of icodextrin peritoneal dialysis solution on cell proliferation in vitro. Adv Perit Dial 1999; 15: 17–20
   PubMedGoogle Scholar
• Ha H, Cha MK, Choi HN, Lee HB. Effects of peritoneal dialysis solutions on the secretion of growth factors and extracellular matrix proteins by human peritoneal mesothelial cells. Perit Dial Int 2002; 22: 171–7
   PubMed Web of Science ®Google Scholar
• Gotloib L, Wajsbrot V, Shostak A. Mesothelial dysplastic changes and lipid peroxidation induced by 7.5% icodextrin. Nephron 2002; 92: 142–55
   PubMed Web of Science ®Google Scholar
• Teppo A-M, Metsärinne K, Fyhrquist F. Radioimmunoassay of interleukin-6 in plasma. Clin Chem 1991; 37: 1691–5
   PubMed Web of Science ®Google Scholar
• Elsner J, Sach M, Knopf HP, Norqauer J, Kapp A, Schollmeyer P, et al. Synthesis and surface expression of ICAM-1 in polymorphonuclear neutrophilic leukocytes in normal subjects and during inflammatory disease. Immunobiology 1995; 193: 456–64
   PubMed Web of Science ®Google Scholar
• Laurent T, Fraser J. Hyaluronan. FASEB J 1992; 6: 2397–404
   PubMed Web of Science ®Google Scholar
• Ho-dac-Pannekeet MM, Hiralall JK, Struijk DG, Krediet RT. Longitudinal follow-up of CA125 in peritoneal effluent. Kidney Int 1997; 51: 888–93
   PubMed Web of Science ®Google Scholar
• Visser CE, Brouwer-Steenbergen JJ, Betjes MG, Koomen GC, Beelen RH, Krediet RT. Cancer antigen 125: a bulk marker for the mesothelial mass in stable peritoneal dialysis patients. Nephrol Dial Transplant 1995; 10: 64–9
   PubMedGoogle Scholar
• Martikainen T, Ekstrand A, Honkanen E, Teppo A-M, Gronhagen-Riska C. Cytokines and other soluble factors in dialysate—indicators of altered peritoneal function?. Scand J Urol Nephrol 2002; 36: 450–4
   PubMed Web of Science ®Google Scholar
• Haraldsson B. Assessing the peritoneal dialysis capacities of individual patients. Kidney Int 1995; 47: 1187–98
   PubMed Web of Science ®Google Scholar
• Van Biesen W, Carlsson O, Bergia R, Brauner M, Christensson A, Genestier S, et al. Personal dialysis capacity (PDC(TM)) test: a multicentre clinical study. Nephrol Dial Transplant 2003; 18: 788–96
   PubMed Web of Science ®Google Scholar
• Danielski M, Ikizler TA, McMonagle E, Kane JC, Pupim L, Morrow J, et al. Linkage of hypoalbuminemia, inflammation, and oxidative stress in patients receiving maintenance hemodialysis therapy. Am J Kidney Dis 2003; 42: 286–94
   PubMed Web of Science ®Google Scholar
• Menon V, Wang X, Greene T, Beck GJ, Kusek JW, Marcovina SM, et al. Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease. Am J Kidney Dis 2003; 42: 44–52
   PubMed Web of Science ®Google Scholar
• Herzig KA, Purdie DM, Chang W, Brown AM, Hawley CM, Campbell SB, et al. Is C-reactive protein a useful predictor of outcome in peritoneal dialysis patients?. J Am Soc Nephrol 2001; 12: 814–21
   PubMed Web of Science ®Google Scholar
• Wang A, Woo J, Lam C, Wang M, Sea M, Lui S, et al. Is a single time point C-reactive protein predictive of outcome in peritoneal dialysis patients?. Perit Dial Int 2003; 23: 174–83
   PubMedGoogle Scholar
• Cueto-Manzano AM, Quintana-Pina E, Correa-Rotter R. Long-term CAPD survival and analysis of mortality risk factors: 12-year experience of a single Mexican center. Perit Dial Int 2001; 21: 148–53
   PubMed Web of Science ®Google Scholar
• Yudkin J. Adipose tissue, insulin action and vascular disease: inflammatory signals. Int J Obes Relat Metab Disord 2003; 27: S25–8
   PubMed Web of Science ®Google Scholar
• Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J 2001; 15: 43–58
   PubMed Web of Science ®Google Scholar